NCT04019197View on ClinicalTrials.gov

Effects of Semaglutide in HIV-Associated Lipohypertrophy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

108

Participants

Timeline

Start Date

May 16, 2019

Primary Completion Date

September 30, 2023

Study Completion Date

March 31, 2025

Conditions
HIV/AIDSLipohypertrophyObesity
Interventions
DRUG

Semaglutide Injectable Product

semaglutide subcutaneous injection

DRUG

Placebo

placebo injection

Trial Locations (2)

29425

Medical University of South Carolina, Charleston

44106

Case Western Reserve University, Cleveland

All Listed Sponsors
collaborator

Medical University of South Carolina

OTHER

collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Case Western Reserve University

OTHER